Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)

Blood

Volumn 101, Issue 8, 2003, Pages 3142-3149

  Guan, Yinghui ^a   Gerhard, Brigitte ^a   Hogge, Donna E ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; PYRONINE; STEEL FACTOR; THYMIDINE; TRITIUM; FLT3 LIGAND PROTEIN; MEMBRANE PROTEIN; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ASSAY; CELL CYCLE; CELL CYCLE G0 PHASE; CELL ISOLATION; CELL SELECTION; CELL STIMULATION; CELL SUBPOPULATION; COLONY FORMING CELL; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING; STEM CELL; ACUTE NONLYMPHOCYTIC LEUKEMIA; ANIMAL; AUTOCRINE EFFECT; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL DIVISION; CELL SEPARATION; CULTURE MEDIUM; DNA REPLICATION; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; MIDDLE AGED; MOUSE MUTANT; MYELOMONOCYTIC LEUKEMIA; NONOBESE DIABETIC MOUSE; PATHOLOGY; RADIATION CHIMERA; TRANSPLANTATION;

ADULT; AGED; ANIMALS; AUTOCRINE COMMUNICATION; CELL DIVISION; CELL SEPARATION; CULTURE MEDIA, SERUM-FREE; DNA REPLICATION; FEMALE; G0 PHASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERLEUKIN-3; LEUKEMIA, MYELOMONOCYTIC, ACUTE; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; RADIATION CHIMERA; STAINING AND LABELING; STEM CELL FACTOR; TUMOR STEM CELLS;

EID: 0037606054     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3062     Document Type: Article

References (49)

1. McCulloch EA. Stem cells in normal and leukemic hemopoiesis. Blood. 1983;62:1-13.
2. + subpopulations. Blood. 1995;86:2906-2912.
3. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-736.
4. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierarchy in human acute myeloid leukemia progenitor cells. Blood. 1996;87:4754-4761.
5. Ailles LE, Gerhard B, Kawagoe H, Hogge DE. Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999;94:1761-1772.
6. Buick RN, Till JE, McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukemia. Lancet. 1977;1:862-863.
7. Ailles LE, Gerhard B, Hogge DE. Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood. 1997;90:2555-2564.
8. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367:645-648.
9. Ailles LE, Humphries RK, Thomas TE, Hogge DE. Retroviral marking of acute myelogenous leukemia progenitors that initiate long-term culture and growth in immunodeficient mice. Exp Hematol. 1999;27:1609-1620.
10. Minden MD, Till JE, McCulloch EA. Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). Blood. 1978;52:592-600.
11. Ponchio L, Conneally E, Eaves C. Quantitation of the quiescent fraction of long-term culture-initiating cells in normal human blood and marrow and the kinetics of their growth factor-stimulated entry into S-phase in vitro. Blood. 1995;86:3314-3321.
12. Guan Y, Hogge DE. Proliferative status of primitive hematopoietic progenitors from patients with acute myelogenous leukemia (AML). Leukemia. 2000;14:2135-2141.
13. Shapiro HM. Flow cytometric estimation of DNA and RNA content in intact cells stained with Hoechst 33342 and pyronin Y. Cytometry. 1981;2:143-150.
14. 1 phase of the cell cycle. Blood. 1997;90:4384-4393.
15. + cells in non-obese diabetic/severe combined immune-deficient mice. Blood. 1998;92:2641-2649.
16. Schumacher HR. Acute Leukemia: Approach to Diagnosis. New York, NY: Igaku-Shoin; 1990.
17. Shuftz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol. 1995;154:180-191.
18. Holyoake T, Jiang X, Eaves C, Eaves A. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood. 1999;94:2056-2064.
19. Lengauer C, Green ED, Cremer T. Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification. Genomics. 1992;13:826-828.
20. Verlinden SF, van Es HH, van Bekkum DW. Serial bone marrow sampling for long-term follow up of human hematopoiesis in NOD/SCID mice. Exp Hematol. 1998;26:627-630.
21. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemic cells in long-term culture due to a defect at the leukemic stem cell level. Proc Natl Acad Sci U S A. 1992;89:6192-6196.
22. Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ. Unregulated proliferation of primitive chronic myeloid leukemia progenitors in the presence of normal marrow adherent cells. Proc Natl Acad Sci U S A. 1986;83:5306-5310.
23. Terpstra W, Ploemacher RE, Prins A, et al. Fluorouracil selectively spares acute myeloid leukemia cells with long-term growth abilities in immunodeficient mice and in culture. Blood. 1996;88:1944-1950.
24. Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood. 2001;98:2301-2307.
25. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE. Expression of Hox genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia. 1999;13:687-698.
26. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukaemia cells with long-term proliferative ability in vitro and in vivo. Blood. 1997;89:3104-3112.
27. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst. 1995;87:895-902.
28. Cashman J, Clark-Lewis I, Eaves A, Eaves C. Stromal derived factor-1 inhibits the cycling of very primitive human hematopoietic cells in vitro and in NOD/SCID mice. Blood. 2002;99:792-799.
29. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1α is the endogenous chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood. 1998;92:2338-2344.
30. Eaves CJ, Cashman JD, Kay RJ, et al. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood. 1991;78:110-117.
31. Oster W, Cicco NA, Klein H, et al. Participation of the cytokines interleukin 6, tumor necrosis factor-α, and interleukin 1-β secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia. J Clin Invest. 1989;84:451-57.
32. Bradbury D, Rogers S, Reilly IA, Kozlowski R, Russell NH. Role of autocrine and paracrine production of granulocyte-macrophage colony-stimulating factor and interleukin-1 β in the autonomous growth of acute myeloblastic leukaemia cells - studies using purified CD34-positive cells. Leukemia, 1992;6:562-566.
33. Zheng R, Baldwin BR, Levis M, et al. Co-expression of the FLT3 receptor and its ligand FL, by primary AML cells [abstract]. Blood. 2001;98:90a.
34. Young DC, Griffin JD. Autocrine secretion of GMCSF in acute myeloblastic leukemia. Blood. 1986 68:1178-1181.
35. Lowenberg B, van Putten WLJ, Touw IP, Delwel R, Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med. 1991;328:614-619.
36. Russell NH, Hunter AE, Bradbury D, Zhu YM, Keith F. Biological features of leukaemic cells associated with autonomous growth and reduced survival in acute myeloblastic leukaemia. Leuk Lymphoma. 1995;16:223-229.
37. + cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood, 2001;97:3075-3085.
38. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333-1337.
39. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631.
40. Bombouts WJC, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000;14:675-683.
41. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98:1752-1759.
42. Kiyoi K; Naoe T, Yokota S, et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia. 1997;11:1447-1452.
43. Jordan CT, Phillips GL, Rizzieri DA, Luger SM, Grimes B, Upchurch D. Cell cycle analyses and apoptosis in primitive leukemic and normal cells [abstract]. Blood. 1999;94:687a.
44. - progenitor cells from patients with acute myeloid leukemia. Blood. 2001;97:3882-3889.
45. 1 transcript levels as an indication of resistant disease in acute myelogenous leukaemia. Br J Haematol. 1990;75:340-345.
46. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol. 1996;14:2150-2159.
47. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood. 1997;90:2952-2961.
48. Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood. 1998;91:2722-2730.
49. Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GMCSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia. 1999;13:1214-1220.